Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

OBJECTIVE: To evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent for treating coronavirus 2019 (COVID-19). METHODS: A retrospective cohort study was conducted at two general hospitals during the study period of December 2020 to May 2021. Mild COVID-19 patients with risk fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Yeon, Lee, Jee Young, Ko, Jae-Hoon, Hyun, Miri, Kim, Hyun Ah, Cho, Seongcheol, Lee, Yong Dae, Song, Junghoon, Shin, Seunghwan, Peck, Kyong Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657590/
https://www.ncbi.nlm.nih.gov/pubmed/34899724
http://dx.doi.org/10.3389/fimmu.2021.772320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657590/
https://www.ncbi.nlm.nih.gov/pubmed/34899724
http://dx.doi.org/10.3389/fimmu.2021.772320

Ejemplares similares